Nanite Receives Funding to Employ
SAYERTM Platform to Develop Non-Viral
Delivery Vehicles to Express Neutralizing Antibodies In Vivo
from the Bill & Melinda Gates Foundation
BOSTON, May 8, 2024
/PRNewswire/ -- Nanite, Inc. today announced a $1.8M grant from the Bill & Melinda Gates
Foundation to design and optimize polymeric delivery vehicles to
deliver DNA-encoded therapeutics.
Nanite's proprietary SAYERTM platform combines
AI-driven polymer design with multiplexed in vivo screening to
develop best-in-class polymer nanoparticles [PNPs] for
tissue-specific delivery. SAYER has demonstrated strong delivery
efficiency and high tissue specificity, potentially overcoming
limitations of viral vectors and lipid nanoparticles [LNPs].
In the research project funded by the foundation, Nanite will
employ the SAYER platform to design and optimize polymeric delivery
vehicles to deliver DNA-encoded therapeutics, thereby durably
producing therapeutic antibodies in vivo. Success would
represent a significant breakthrough in HIV management,
particularly in populations with limited access to medical
care.
"Nanite's research, with support from the Gates Foundation, is
consequential in discovering safe polymeric nanoparticles for a
transformative treatment for HIV," notes Nanite Chief Business
Officer, Thomas X. Neenan, PhD. "One
of our long-stated goals is to develop technologies that allow the
benefits of gene therapy to be accessible to a wider patient
population, particularly in underserved communities. Nanite
is dedicated to accelerating the impact of genetic medicine for the
treatment of HIV."
ABOUT NANITE:
Nanite, Inc. is a non-viral
gene delivery company developing programmable, tissue-specific
polymer nanoparticles (PNPs) for a broad range of modalities and
indications. Powered by our AI-driven platform,
SAYERTM, Nanite is building the next generation of
non-viral delivery vehicles – programmable, targeted, and safe –
for a new wave of genetic medicines. SAYER applies state-of-the-art
machine learning-methods to combine high-throughput experimental
and computational polymer chemistry to design fit-for-purpose
delivery vehicles. Nanite is headquartered in Boston, MA. For more information, visit
https://nanitebio.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nanite-awarded-1-8m-to-develop-ai-driven-gene-therapy-for-hiv-302138913.html
SOURCE Nanite Inc.